Investigation of Color in a Fusion Protein Using Advanced Analytical Techniques: Delineating Contributions from Oxidation Products and Process Related Impurities

被引:20
作者
Song, Hangtian [1 ]
Xu, Jianlin [2 ]
Jin, Mi [2 ,5 ]
Huang, Chao [2 ]
Bongers, Jacob [3 ]
Bai, He [3 ]
Wu, Wei [1 ]
Ludwig, Richard [3 ]
Li, Zhengjian [4 ]
Tao, Li [3 ]
Das, Tapan K. [3 ]
机构
[1] Bristol Myers Squibb Co, Biol Mol & Analyt Dev, Bloomsbury, NJ USA
[2] Bristol Myers Squibb Co, Biol Proc Dev, East Syracuse, NY USA
[3] Bristol Myers Squibb Co, Biol Mol & Analyt Dev, Hopewell, NJ USA
[4] Bristol Myers Squibb Co, Biol Proc Dev, Devens, MA USA
[5] Teva Pharmaceut, 145 Brandywine Pkwy, W Chester, PA 19380 USA
关键词
color; histidine; mass spectrometry; oxidation; process development; tryptophan; ultra-performance liquid chromatography; AMINO-ACID-RESIDUES; MONOCLONAL-ANTIBODY; TRYPTOPHAN OXIDATION; N-FORMYLKYNURENINE; SWISS-MODEL; EXTRACELLULAR-MATRIX; CRYSTAL-STRUCTURE; CROSS-LINK; HISTIDINE; PEPTIDES;
D O I
10.1007/s11095-015-1839-3
中图分类号
O6 [化学];
学科分类号
0703 ;
摘要
Discoloration of protein therapeutics has drawn increased attention recently due to concerns of potential impact on quality and safety. Investigation of discoloration in protein therapeutics for comparability is particularly challenging primarily for two reasons. First, the description of color or discoloration is to certain extent a subjective characteristic rather than a quantitative attribute. Secondly, the species contributing to discoloration may arise from multiple sources and are typically present at trace levels. Our purpose is to development a systematic approach that allows effective identification of the color generating species in protein therapeutics. A yellow-brown discoloration event observed in a therapeutic protein was investigated by optical spectroscopy, ultra-performance liquid chromatography, and mass spectrometry (MS). Majority of the color generating species were identified as oxidatively modified protein. The location of the oxidized amino acid residues were identified by MS/MS. In addition, the impact of process-related impurities co-purified from media on discoloration was also investigated. Finally a semi-quantitative scale to estimate the contribution of each color source is presented, which revealed oxidized peptides are the major contributors. A systematic approach was developed for identification of the color generating species in protein therapeutics and for estimation of the contribution of each color source.
引用
收藏
页码:932 / 941
页数:10
相关论文
共 65 条
  • [21] Extensive investigations on oxidized amino acid residues in H2O2-treated Cu,Zn-SOD protein with LC-ESI-Q-TOF-MS, MS/MS for the determination of the copper-binding site
    Kurahashi, T
    Miyazaki, A
    Suwan, S
    Isobe, M
    [J]. JOURNAL OF THE AMERICAN CHEMICAL SOCIETY, 2001, 123 (38) : 9268 - 9278
  • [22] Site-Specific Tryptophan Oxidation Induced by Autocatalytic Reaction of Polysorbate 20 in Protein Formulation
    Lam, Xanthe M.
    Lai, William G.
    Chan, Edwin K.
    Ling, Victor
    Hsu, Chung C.
    [J]. PHARMACEUTICAL RESEARCH, 2011, 28 (10) : 2543 - 2555
  • [23] Lam XM, 2001, Antibody formulation, Patent No. [US6171586 Bl, 6171586]
  • [24] A critical evaluation of self-interaction chromatography as a predictive tool for the assessment of protein-protein interactions in protein formulation development: A case study of a therapeutic monoclonal antibody
    Le Brun, Virginie
    Friess, Wolfgang
    Bassarab, Stefan
    Muehlau, Silke
    Garidel, Patrick
    [J]. EUROPEAN JOURNAL OF PHARMACEUTICS AND BIOPHARMACEUTICS, 2010, 75 (01) : 16 - 25
  • [25] Characterization of the Degradation Products of a Color-Changed Monoclonal Antibody: Tryptophan-Derived Chromophores
    Li, Yiming
    Polozova, Alla
    Gruia, Flaviu
    Feng, Jinhua
    [J]. ANALYTICAL CHEMISTRY, 2014, 86 (14) : 6850 - 6857
  • [26] Lucas K, 2012, Methods for inhibiting yellow color formation in a composition, Patent No. [US20120183531 Al, 20120183531]
  • [27] Ultraviolet Spectroscopy as a Tool in Therapeutic Protein Development
    Mach, Henryk
    Middaugh, C. Russell
    [J]. JOURNAL OF PHARMACEUTICAL SCIENCES, 2011, 100 (04) : 1214 - 1227
  • [28] Crystal structure of human germline antibody 3-23/B3
    Malia, Thomas J.
    Obmolova, Galina
    Almagro, Juan Carlos
    Gilliland, Gary L.
    Teplyakov, Alexey
    [J]. MOLECULAR IMMUNOLOGY, 2011, 48 (12-13) : 1586 - 1588
  • [29] Opalescence of an IgG2 Monoclonal Antibody Solution as it Relates to Liquid-Liquid Phase Separation
    Mason, Bruce D.
    Zhang, Le
    Remmele, Richard L., Jr.
    Zhang, Jifeng
    [J]. JOURNAL OF PHARMACEUTICAL SCIENCES, 2011, 100 (11) : 4587 - 4596
  • [30] Effect of pH and Light on Aggregation and Conformation of an IgG1 mAb
    Mason, Bruce I.
    Schoeneich, Christian
    Kerwin, Bruce A.
    [J]. MOLECULAR PHARMACEUTICS, 2012, 9 (04) : 774 - 790